PK-guided individualized preventive treatment drives "3D" improvements in joint health

The Chinese Guidelines for the Management of Hemophilia (2021 Edition) states that ^PK-guided individualized preventive treatment matches a patient's amount of coagulation factor infusion to their PK prediction needs, ensuring that each patient receives adequate treatment to achieve similar coagulation factor levels

In 2021, the first Chinese Expert Consensus on Pharmacokinetics Guiding the Treatment of Hemophilia A^, was released2, providing guidance for the detection, interpretation and application of FVIII PK in the clinical practice of hemophilia A in ^China2

In this issue, Xiaobian will join you to witness how PK-guided personalized preventive treatment can promote "3D" to improve joint health

Recurrent bleeding in the joints, if not treated promptly, may eventually lead to impaired joint function or even ^deformity1

A non-interventional, prospective, multicenter study conducted by R.

Glucoid concentrations >1% are key factors in the success of preventive treatment, trough concentrations <1% will occur frequently and spontaneously, and the incidence of joint lesions in early adulthood will reach more than 90%⁴

A study ⁵ published by Congling Gu et al.
, evaluating the outcomes of PK-guided prophylaxis versus standard prophylaxis and developing discrete event simulation models to simulate the clinical outcomes of 10,000 adult patients with hemophilia A in China receiving 1 year of treatment, showed ^{that 5}:

• The proportion of patients with PK-guided individualized prophylaxis maintained at 1-5 IU/dL was higher (62.
  7% vs 94.
  3%)
  compared with standard prophylaxis therapy.
  
  

• Under PK-guided individualized prophylaxis, the cost of treatment (US$ 159,620.
  93 vs US$ 148,641.
  47) and the cost of treatment for bleeding events (US$ 4753.
  39 vs US$ 4546.
  43) were lower
  than standard preventive treatment.
  
  

The risk of joint lesions and low bone density in hemophilia patients is significantly increased compared with the general population, and physical activity can promote the health of the osteoarticular system, prevent or reduce joint lesions, reduce the risk of joint ^bleeding1, and help "3D" improve joint health
.

A study conducted by Pasca S et al.
, including 14 patients with moderate to severe hemophilia A who received PK-guided individualized preventive therapy with rAHF-PFM, showed that PK-guided individualized preventive therapy promoted patient participation in physical activity, with 8 patients starting (3/8 cases) or continuing (5/8 patients) after treatment
.

Among them, 3 patients played soccer 3 times a week, 2 patients played basketball 3 times a week, and 3 patients swam 3 times a ^week6
.

PK-guided individualized preventive treatment, with its "skills", plays a key role
in promoting "3D" improvements in joint health.

In the future, it is believed that more hemophilia A patients can have healthier joints and a freer life
under the individualized treatment guided by PK.

References:

1.
Yang Renchi Editor-in-Chief.
Guidelines for the Management of Hemophilia in China (2021 Edition).
Peking Union Medical College Press.

2.
Chinese Hemohilia Collaborative Group, Chinese Clinical Research
.

2021; 34(5):577-581,591.

3.
R.
Klamroth,et al.
Presented at the 15th European Association for Haemophilia and Allied Disorders(EAHAD),2022; Abstracts PO105

4.
Ljung R,et al.
Thromb Haemost.
2016 May 2; 115(5):913-20.

5.
Congling Gu,et al.
Adv Ther.
2022 Jun 30

6.
Pasca S, et al.
Thromb Res.
2019 Nov; 183:1-3.

Approval number: VV-MEDMAT-74626

Approval date: 9/21/2022

Expires: 9/20/2024

statement

This information is intended to help healthcare professionals better understand the latest developments
in the field of related diseases.

The information content published by this platform does not mean that it agrees with its description and views, but only provides more information
.

If it involves copyright issues, please contact us and we will deal with them
as soon as possible.

The information provided in this information should not in any way replace professional medical guidance and should not be considered as a medical advice
.

If such information is used for purposes other than information information, the platform, the author and Takeda do not assume the relevant responsibility
.

Poke "Read the original article" to see more